MARKET

RDUS

RDUS

Radius Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.07
-0.71
-4.50%
After Hours: 15.07 0 0.00% 16:00 12/01 EST
OPEN
15.97
PREV CLOSE
15.78
HIGH
15.97
LOW
15.00
VOLUME
320.15K
TURNOVER
--
52 WEEK HIGH
23.22
52 WEEK LOW
10.15
MARKET CAP
701.47M
P/E (TTM)
-6.2029
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Radius Health, Inc. (NASDAQ:RDUS) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Radius Health, Inc. (NASDAQ:RDUS) last week reported its latest third-quarter results, which makes it a good time for...
Simply Wall St. · 11/09 12:39
Radius Health (RDUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 10/29 17:35
Radius Health, Inc.: Progress Since May 2020
* Completed enrollment in 3 pivotal clinical trials; multiple data read outs in Q4 2021 * Released meaningful abaloparatide histomorphometry data at recent ASBMR meeting * Completed two business development transactions with existing oncology assets * Repositioned commercial effort to focus on high risk/fracture patient segment * Increased current operating leverage by re-engineering components of infrastructure WALTHAM, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since May 2020. The Company will provide further updates during its third quarter earnings call and at subsequent investor conferences. The key areas of activity included as part of its update are outlined below.Clinical and Regulatory:•Patient enrollment completed for 3 Pivotal Phase III trials:     ºATOM study evaluating abaloparatide injection for potential use in osteoporotic men with high risk of fracture   ºwearABLe study evaluating the effects on bone mineral density of abaloparatide delivered via a novel transdermal system   ºEMERALD study for use of elacestrant to treat ER+/HER2- advanced or metastatic breast cancer in men and postmenopausal women •Japan: Pivotal Phase III trial of abaloparatide injection to treat both men and postmenopausal women     ºExecution success by Radius partner, Teijin Pharma   ºAchieved primary endpoint: for osteoporotic patients with high risk for fractures   ºNDA submitted •Europe     ºSeeking guidance and clarity regarding possible regulatory re-submission •Histomorphometry Phase 2 Study data     ºPresented at American Society for Bone and Mineral Research (ASBMR) in September   ºStudy assessed the early effect of abaloparatide at the tissue level and demonstrated significant increases in bone formation after three months in postmenopausal women with osteoporosis Business Development•Completed transaction with Menarini Group for Elacestrant, an oral SERD   ºMenarini licenses global development and commercial rights   ºReceived $30 million as an upfront payment and up to $320 million in additional milestones along with tiered low to mid-teen royalties   ºPhase 3 development costs to be fully reimbursed by Menarini Group •Completed transaction with Ellipses Pharma for RAD 140, an oral SARM   ºEllipses responsible for all clinical development and advancement   ºReceive low double-digit percentage of future economics received by Ellipses US TYMLOS Commercial Business•Re-engineering internal operations     ºCombined market access with sales and marketing under one umbrella   ºReduced sales territories from 159 to 109 and sales regions from 19 to 13   ºAdjusted incentive compensation plan to incentivize growth in PMO patients at high risk for fracture • Performance Measurement     ºNet new patients on TYMLOS per month vs. 3 month trailing moving average   ºTotal patients and duration of patients on TYMLOS vs. 3 month moving average   ºNo longer focused on anabolic market share as Radius/TYMLOS business driver • Transparency of TYMLOS performance metrics for the marketplace     ºCommunicate Radius net new patients each month, commencing November 2020   ºCommunicate total Radius patients quarterly, starting with Q1, 2021 results   ºShare avg. Radius patient months on therapy quarterly, starting Q2, 2021 results Increasing Current Operating Leverage: * Real estate goal: reduce from ~ 60,000 to ~ 12,000 sq. ft. actioning a hybrid work model * Reduced silos at the senior level: consolidated commercial; integrated human resources, information technology, compliance, legal, QA, supply chain and real estate * Total FTE headcount reduced from ~ 400 in 2019 to 315 as of Oct. 1, 2020, an absolute reduction of more than 20 % * Capital allocation: adjusting abaloparatide planned clinical programs to focus on growth through patient segmentation and utilizing existing data with precision of message (s) * Net new patient numbers for Radius: September and October demonstrating growth from mid-year COVID-19 slow downAbout TYMLOS (abaloparatide) injectionTYMLOS® (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.IMPORTANT SAFETY INFORMATIONWARNING: RISK OF OSTEOSARCOMA * Abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma (a malignant bone tumor) in male and female rats. The effect was observed at systemic exposures to abaloparatide ranging from 4 to 28 times the exposure in humans receiving the 80-mcg dose. It is unknown if TYMLOS will cause osteosarcoma in humans. * The use of TYMLOS is not recommended in patients at increased risk of osteosarcoma including those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, or prior external beam or implant radiation therapy involving the skeleton. * Cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient's lifetime is not recommended. Orthostatic Hypotension: Orthostatic hypotension may occur with TYMLOS, typically within 4 hours of injection. Associated symptoms may include dizziness, palpitations, tachycardia or nausea, and may resolve by having the patient lie down. For the first several doses, TYMLOS should be administered where the patient can sit or lie down if necessary.Hypercalcemia: TYMLOS may cause hypercalcemia. TYMLOS is not recommended in patients with pre-existing hypercalcemia or in patients who have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, because of the possibility of exacerbating hypercalcemia.Hypercalciuria and Urolithiasis: TYMLOS may cause hypercalciuria. It is unknown whether TYMLOS may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.Adverse Reactions: The most common adverse reactions (incidence ≥2%) are hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain and vertigo.INDICATIONS AND USAGETYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures.Limitations of UseBecause of the unknown relevance of the rodent osteosarcoma findings to humans, cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient's lifetime is not recommended.For the TYMLOS prescribing information, including Boxed Warning, please visit www.tymlospi.comForward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the results of regulatory submissions and oversight; success of our commercial operations; success of our clinical trials and preclinical studies; risks related to manufacturing, supply and distribution; success of any collaboration, partnership, license or similar agreements; achievement of milestones; receipt of royalties or other future contingent payments; ability to implement pricing increases. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, or SEC, including under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ending December 31, 2019 and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.Investor Relations Contact: Elhan Webb, CFA Email: ewebb@radiuspharm.com Phone: 617-551-4011
GlobeNewswire · 10/21 12:15
Radius Health to Announce Third Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, November 5, 2020
WALTHAM, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update. Conference Call Information: Domestic Dial-In Number: (866) 323-7965 International Dial-In Number: (346) 406-0961 Conference ID: 9147422A replay of the conference call will be available on November 5 at 11:30 a.m. ET and live audio webcast of the call will be archived on the Company's website for ninety days. To access the replay, dial (855) 859-2056 U.S. or (404) 537-3406 for International, using conference ID number 9147422. The live audio webcast of the call can be accessed from the Investors section of the Company’s website, https://ir.radiuspharm.com/events-and-presentations. The full text of the announcement and financial results will also be available on the Company’s website.About RadiusRadius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes the investigational use of abaloparatide injection for the treatment of men with osteoporosis, an investigational abaloparatide-patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer out-licensed to Menarini Group. For more information, please visit www.radiuspharm.comInvestor & Media Relations Contact: Elhan Webb, CFA Email: ewebb@radiuspharm.com Phone: 617-551-4011
GlobeNewswire · 10/20 21:15
Peter A. Schwartzman Joins Radius Health, Inc.
Schwartzman joins the newly formed Capital, Strategy, & Transactions GroupWALTHAM, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that Peter A. Schwartzman is joining the company as Vice President in the newly formed Capital, Strategy
GlobeNewswire · 10/06 20:30
Would Shareholders Who Purchased Radius Health's (NASDAQ:RDUS) Stock Five Years Be Happy With The Share price Today?
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we...
Simply Wall St. · 10/06 19:07
Is Radius Health Inc (RDUS) Going to Burn These Hedge Funds?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the second quarter. You can find articles about an individual
Insider Monkey · 10/05 17:46
Radius Health Divests RAD 140 Program to Ellipses Pharma
Radius Health, Inc. (Nasdaq: RDUS) announced today that the company has successfully sold its second oncology pipeline asset – RAD 140 - to Ellipses Pharma Limited, completing Radius’s divestment of its oncology assets. Under the agreement, Ellipses Pharma will be responsible for the clinical development
GlobeNewswire · 10/01 13:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RDUS. Analyze the recent business situations of Radius Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RDUS stock price target is 20.25 with a high estimate of 25.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 209
Institutional Holdings: 60.40M
% Owned: 129.77%
Shares Outstanding: 46.55M
TypeInstitutionsShares
Increased
41
4.04M
New
41
-1.12M
Decreased
45
3.02M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.30%
Pharmaceuticals & Medical Research
+0.62%
Key Executives
Chairman/Independent Director
Owen Hughes
President/Chief Executive Officer/Director
G. Kelly Martin
Chief Financial Officer/Chief Accounting Officer/Treasurer
Dan Dolan
Senior Vice President
Chhaya Shah
Other
Charles Morris
Director
Sean Murphy
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RDUS
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Its clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis, and the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group. Elacestrant is a selective estrogen receptor degrader (SERD) being developed as a once daily oral treatment in patients with advanced estrogen receptor positive, HER2 negative, breast cancer.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Radius Health Inc stock information, including NASDAQ:RDUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDUS stock methods without spending real money on the virtual paper trading platform.